ASCO 2025: Experts gather to showcase their ground-breaking cancer research From 30 May to 3 June, the world’s leading oncologists and researchers, including scientists from The Institute of Cancer ...

Give a monthly donation to help us stay one step ahead of cancer with new smarter and targeted treatments – so that more people will survive blood cancer. Cecelia Brunott (pictured above) was ...

A new genetically engineered virus has delivered a one-two punch against advanced cancers in initial findings from a phase I trial. Researchers found that RP2 – a modified version of the herpes ...

Scientists at The Institute of Cancer Research, London, have found a way to identify people with inflammatory bowel disease (IBD) who are at the highest risk of developing bowel cancer. IBD includes ...

A new type of liquid biopsy test can predict the recurrence of breast cancer in high-risk patients, months or even years before they relapse, research by a team from The Institute of Cancer Research, ...

The Institute of Cancer Research, London, strongly welcomes the decision by NICE to recommend the targeted breast cancer drug, capivasertib, in combination with fulvestrant, for treating the most ...

The overuse of CT scans could cause over 100,000 cases of cancer in the US – with almost 10,000 cases in children, researchers have warned. According to a new modelling study, published in the journal ...

Scientists have shown for the first time that some of the most persistent cancer cells in glioblastoma, a common type of adult brain tumour, rely on a specific enzyme for survival and that inhibiting ...

Pharmacological ‘auditing’ The Phase I clinical trial of capivasertib utilised the Pharmacological Audit Trail approach, which was conceptualised and developed by Professor Workman and colleagues..

A spit test, where a sample can be collected at home, is more accurate at identifying future risk of prostate cancer for some men than the current standard PSA blood test, a new study reports. Results ...

A new AI test can pick out which men with high-risk prostate cancer that has not spread will require life-extending drug abiraterone. Scientists from The Institute of Cancer Research, London, and ...

Thousands of patients with a common type of blood cancer could benefit from a new drug combination, while others could see their disease kept at bay for longer. Research published in the journal Blood ...